Health Condition 1: J988- Other specified respiratory disorders
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: People eligible for inclusion in the home-based PR trial will be: aged >=18 years,confirmed diagnosis of IPF according to ATS/ERS guidelines and willing to provide informed consent. Healthcare professionals will be defined as: Those who have at least1year of experience and work directly with IPF patients, including specialists, nurses and physiotherapists. Family caregivers will be defined as: Those who have and/or care for a family member diagnosed with IPF.
Exclusion criteria
Exclusion criteria: Adults with comorbidities such as severe or unstable cardiovascular, other internal diseases and locomotor difficulties that preclude the exercise or malignant disease or other serious illness which will interfere with participation in the study, will be excluded. Individuals not eligible for the study will be recorded on a study screening log.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility Measures to assess feasibility are provided and include the comprehensive assessment of the feasibility of patient recruitment and the intervention delivery. Acceptability The acceptability of the intervention among adults living with IPF and healthcare staff involved in its delivery will be assessed. Participantsâ?? experience of home-based PR, including any perceived benefits, challenges and changes.Timepoint: At Baseline and 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome measures 1. Socio-demographics 2. Lung health (spirometry data, lung transfer factor, smoking status) 3. Comorbidities 4. Treatments 5. Disease burden (MRC dyspnea grade, CAT) 6. Economic impact of disease (WPAI) 7. Quality of life (EQ-5D-5L, KBILD) 8. Psychological wellbeing (Hospital Anxiety and Depression scale) 9. Physical function (5x sit-to-stand test) 10. Exercise capacity (ISWT, ESWT) Timepoint: At baseline and 6 weeks | — |
Countries
United Kingdom
Contacts
Metro Centre for Respiratory Disease MCRD